HNSBF.US Hansa Biopharma AB (publ)

Healthcare Biotechnology USA Stocks
3.29 USD
Close of Nov 14, 2026
2.90 3.70
Market cap
USD 328M
P/E
-
P/B
8.49x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is HNSBF.US undervalued?

Graham number

The Graham number of Hansa Biopharma AB (publ) cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Hansa Biopharma AB (publ) fundamental analysis

No fundamental analysis for Hansa Biopharma AB (publ) yet.

Hansa Biopharma AB (publ) stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Hansa Biopharma AB (publ)

Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It also develops HNSA-5487, a next gener…

Full company profile